Celularity's Placental-Derived Allogeneic Cell Therapy
Legacy studies employing a single treatment course of two infusions seven days apart demonstrated greatest benefit in three early studies Data support...
Source: globenewswire.com
Page 4 - Nasdaq Celu News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nasdaq Celu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nasdaq Celu Today - Breaking & Trending Today
Celularity Appoints Paul Graves as Chief Communications
Veteran executive brings more than 30 years of biopharmaceutical public relations and public affairs experience...
Source: globenewswire.com
Celularity Reports Third Quarter 2022 Financial Results and
Announced first patient treated in Phase 1/2a clinical trial for CYNK-101 in first-line advanced HER2 positive gastric and gastroesophageal junction...
Source: globenewswire.com
Celularity Presents Preclinical Data on CYNK-101, its
FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing...
Source: globenewswire.com
Celularity Appoints Adrian Kilcoyne, M.D., M.P.H., M.B.A.,
Veteran pharmaceutical executive brings more than 15 years of proven oncology and immunology experience...
Source: globenewswire.com